Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Inclusion Criteria:

1. Age ≥18 years old at the time of signing the informed consent, regardless of gender;

2. Diagnosed with moderate to severe plaque psoriasis;

3. The subject voluntarily signs informed consent before the start of any proceduresrelated to the study, can communicate with the researcher smoothly, understands andis willing to strictly comply with the requirements of this clinical study protocolto complete the study;

4. Patients who have been treated with biologics for ≥12 weeks prior to screening andare in line with the biologics conversion recommendations of the Chinese Guidelinesfor the Treatment of Psoriasis Biologics and Small Molecule Drugs (2024 edition),and who have been screened and evaluated by researchers as eligible for biologicstherapy.

Exclusion Criteria:

1. Patients previously treated with IL-17A inhibitors (IL-17Ai) had primary failure;

2. Patients who had previously used IL-17A inhibitors (IL-17Ai) and experienceddrug-related adverse events leading to drug withdrawal;

3. Patients with severe hypersensitivity to the active ingredient or any excipients ofVunakizumab;

4. Fertile women (defined as all women with physical conditions necessary forpregnancy) and men who are pregnant or unwilling or unable to use highly effectivebirth control during the study period and within 20 weeks after the last receipt ofthe study drug;

5. Patients with clinically important active diseases, such as active tuberculosis,active hepatitis, and active malignant tumors;

6. Any other circumstances that the investigator believes will prevent the subject fromfollowing and completing the study protocol.